KRN2391 is a cyanoamidine derivative with a pyridine ring and a nitroxyl gr
oup. This gives the molecule a dual pharmacological action as both an ATP-s
ensitive K channel (K-ATP) Opener and an organic nitrate. In cerebrovascula
r disease with endothelial dysfunction, such a compound could be advantageo
us to prevent the negative consequences of a reduced synthesis of endogenou
s nitric oxide and endothelium-derived hyperpolarizing factor. The objectiv
e of this study was to characterise the vasodilator action of KRN2391 in a
cerebral artery. As shown in the rabbit basilar artery contracted by endoth
elin-1 KRN2391 elicited a concentration-dependent relaxation. KRN2391 was u
nable to relax arteries contracted by a 60 mM K solution. The KRN2391-induc
ed relaxation of endothelin-l-contracted arteries was unaffected by N-G-nit
ro-L-arginine (0.1 mM), indomethacin (10 mu M) or removal of the endotheliu
m. The guanylate cyclase inhibitors ODQ (10 mu M) and LY53583 (10 mu M), an
d the cGMP phosphodiesterase inhibitor zaprinast (10 mu M) each had no effe
ct on the KRN2391-induced relaxation. Glibenclamide (1 mu M), a blocker of
K-ATP, caused a rightward shift of the concentration-response curve for KRN
2391. The relaxation induced by the prototype K-ATP Opener leveromakalim wa
s inhibited to a similar extent by glibenclamide. Addition of ODQ or LY5358
3, or the calcium-sensitive K channel blockers apamin (0.1 mu M) and charyb
dotoxin (0.1 mu M) in the presence of glibenclamide did not produce a signi
ficant further inhibition of the KRN-induced relaxation. KRN2391 (10 mu M)
did not influence the content of cGMP in the basilar artery, whereas the ni
tric oxide donor 3-morpholino-sydnonimine (0.1 mM) increased the cGMP level
three-fold. Thus, KRN3391 is an effective vasodilator of the rabbit basila
r artery, acting mainly through opening of K-ATP The nitro-moiety of the mo
lecule does not seem to contribute to the relaxant effect in this artery.